Document is current
Any future updates will be listed below
-
Authors
Takahashi, Masahiro https://orcid.org/0000-0003-3019-9869
Yamamoto, Shinya
Yamamoto, Shigenori https://orcid.org/0000-0001-5632-3034
Okubo, Akihiro https://orcid.org/0000-0003-3588-4769
Nakagawa, Yasuaki
Kuwahara, Koichiro https://orcid.org/0000-0003-2670-7170
Matsusaka, Taiji https://orcid.org/0000-0001-9466-4585
Fukuma, Shingo https://orcid.org/0000-0002-8379-8761
Yamamoto, Masamichi
Matsuda, Michiyuki https://orcid.org/0000-0002-5876-9969
Yanagita, Motoko https://orcid.org/0000-0002-0339-9008
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (22gm1210009, 22gm5010002, 22zf0127003h001, 22ek0310020h0001)
MEXT | Japan Society for the Promotion of Science (20H03697, 21K16162, 16H06280)
- License Information
-
More Information
Article History
Received: 10 February 2023
Accepted: 4 November 2024
First Online: 22 November 2024
Competing interests
: MoY has received research grants from Mitsubishi Tanabe Pharma Corp. and Boehringer Ingelheim Co., LTD. MaY has received research grants from Meiji Holdings and Boehringer Ingelheim Co., LTD. and holds patents (JP6593595, US11160879). ShigY was employed by the TMK Project, which was a collaborative project between Kyoto University and Mitsubishi Tanabe Pharma Corp. KK has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Kowa Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Pharma Co., Ltd.), Mitsubishi Tanabe Pharma Corp., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., and Janssen Pharmaceutical K.K.; funded research or joint research expenses from Kowa Co., Ltd., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Novo Nordisk Pharma Ltd., Amgen, Janssen Pharmaceutical K.K., Parexel International Inc., and Astellas Pharma Inc. His affiliated institution (Shinshu University School of Medicine) has received grants from Otsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Nippon Boehringer Ingelheim Co., Ltd., and Kyowa Kirin Co., Ltd., and his department has endowed chairs from Medtronic Japan Co., Ltd., Boston Scientific Japan K.K., Abbott Japan LLC, Japan Lifeline Co.,Ltd., Biotronik Japan, Terumo Corporation, Nipro Corporation, and Cordis Japan G.K. The other authors declare no conflicts of interest.
